FDA Determines Regulatory Review Period for ALHEMO Patent Extension

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for ALHEMO, a human biological product, in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).